Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770780 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
A Phase 1 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03770780 is a Phase 1 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT03770780, a Phase 1 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is a phase 1, double-blind, placebo-controlled crossover study of SAGE-718 using a ketamine challenge, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic response using magnetic resonance imaging in healthy subjects
Interventions
- DRUG Placebo
- DRUG SAGE-718
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2019-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03770780
The ClinicalTrials.gov registry entry for NCT03770780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03770780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03770780 about?
NCT03770780 is a clinical study titled "A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects". This study is a phase 1, double-blind, placebo-controlled crossover study of SAGE-718 using a ketamine challenge, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic response using magnetic resonance imaging in healthy subjects
What is the current status of trial NCT03770780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-11-12. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT03770780?
The interventions under investigation include: Placebo (DRUG), SAGE-718 (DRUG).
Who is sponsoring clinical trial NCT03770780?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.